William J. H. Glasson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William J. H. Glasson has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Beckman
Queensland Ocular Oncology Service at Terrace Eye Centre Brisbane Queensland Australia
3 shared publications - Lindsay A. McGrath
Queensland Ocular Oncology Service, Terrace Eye Centre, Brisbane, Queensland, Australia
2 shared publications - Sunil Warrier
Queensland Ocular Oncology Service, The Terrace Eye Centre, Brisbane, QLD, Australia
2 shared publications Adrian Gibbs
Radiation Oncology Princess Alexandra Hospital Raymond Terrace (ROPART) Brisbane Queensland Australia
1 shared publication- Andrew Pullar
Radiation Oncology Princess Alexandra Hospital Raymond Terrace (ROPART) Brisbane Queensland Australia
1 shared publication - Catherine M. Olsen
Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia
1 shared publication
Latest Publications
- 8 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF8
Phenotypic and Genotypic Risk Factors for Uveal Melanoma in a High Ambient UV Radiation Environment
Background: Most evidence on risk factors for uveal melanoma derives from case–control studies prone to recall bias, and its rarity has limited prospective research. To address these gaps, we applied a population-based case–control design incorporating polygenic risk scores (PRS) and Mendelian randomization (MR) to explore genetic and phenotypic determinants of uveal melanoma risk. Methods: The study was conducted in Queensland, Australia. Incident uveal melanoma cases diagnosed between 2011 and 2022 were recruited through specialist ocular oncology clinics. Controls were participants in the QSkin Sun and Health Study, a prospective cohort of 43,794 adults 40 to 69 years of age at baseline (2010–2011). Demographic, phenotypic, and sun exposure factors were harmonized across studies. PRSs were calculated for pigmentation traits and nevus characteristics using genome-wide association study (GWAS) datasets, and MR was used to assess potential causal relationships with uveal melanoma risk. Results: Among 485 uveal melanoma cases and 43,724 controls, several phenotypic traits were strongly associated with uveal melanoma risk: male sex, blue or light eye color, inability to tan, freckling, and high nevus density. A family history of cutaneous melanoma and a personal history of keratinocyte cancer were also associated with higher risk. PRS analyses confirmed significant associations for eye color and freckling. MR analyses supported causal relationships between lighter eye color, freckling propensity, and reduced tanning ability and uveal melanoma risk. Conclusions: These findings provide genetic evidence supporting a causal role for pigmentation-related traits in uveal melanoma susceptibility. Impact: This evidence may help refine risk assessment and inform counseling for individuals with suspicious ocular lesions.
- 8 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- p. OF1-OF8
Phenotypic and Genotypic Risk Factors for Uveal Melanoma in a High Ambient UV Radiation Environment
Background: Most evidence on risk factors for uveal melanoma derives from case–control studies prone to recall bias, and its rarity has limited prospective research. To address these gaps, we applied a population-based case–control design incorporating polygenic risk scores (PRS) and Mendelian randomization (MR) to explore genetic and phenotypic determinants of uveal melanoma risk. Methods: The study was conducted in Queensland, Australia. Incident uveal melanoma cases diagnosed between 2011 and 2022 were recruited through specialist ocular oncology clinics. Controls were participants in the QSkin Sun and Health Study, a prospective cohort of 43,794 adults 40 to 69 years of age at baseline (2010–2011). Demographic, phenotypic, and sun exposure factors were harmonized across studies. PRSs were calculated for pigmentation traits and nevus characteristics using genome-wide association study (GWAS) datasets, and MR was used to assess potential causal relationships with uveal melanoma risk. Results: Among 485 uveal melanoma cases and 43,724 controls, several phenotypic traits were strongly associated with uveal melanoma risk: male sex, blue or light eye color, inability to tan, freckling, and high nevus density. A family history of cutaneous melanoma and a personal history of keratinocyte cancer were also associated with higher risk. PRS analyses confirmed significant associations for eye color and freckling. MR analyses supported causal relationships between lighter eye color, freckling propensity, and reduced tanning ability and uveal melanoma risk. Conclusions: These findings provide genetic evidence supporting a causal role for pigmentation-related traits in uveal melanoma susceptibility. Impact: This evidence may help refine risk assessment and inform counseling for individuals with suspicious ocular lesions.
- 7 October 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Choroidal Melanoma Treated With Ruthenium‐106 Eye Plaque Brachytherapy: Results of an Australian Statewide Service From November 2020 to January 2025
Introduction: Uveal melanoma is a rare but aggressive malignancy, predominantly affecting the choroid. This study is the first retrospective review performed on adult choroidal melanoma patients treated with Ruthenium‐106 plaque brachytherapy in Queensland. Method: The study period was November 2020 to January 2025, where patient, tumour, and treatment factors, as well as local control, salvage treatments, radiation retinopathy, and visual acuity were assessed at 6, 12, 24, and 36 months post‐treatment. Results: A total of 151 patients with a mean tumour thickness of 3.85 mm and mean largest basal diameter of 10.2 mm received treatment. A dose of 100 Gy to the tumour apex was prescribed to 88.7% of patients. The short‐term risk factor for disease progression was tumour thickness (odds ratio [OR] 2.01, 95% confidence interval [CI], 1.11–3.87; p = 0.025), whereas tumour to optic nerve distance was a protective factor in both the short‐ (OR 0.55, 95% CI 0.31–0.82; p = 0.013) and long‐term (OR 0.75, 95% CI 0.60–0.90; p = 0.005). At 36 months post‐treatment, local control was 89.5%, the enucleation rate was 3.3%, tumour thickness (OR 1.77, 95% CI 1.1–2.98; p = 0.022) and sclera dose (OR 1.01, 95% CI 1–1.01; p = 0.045) were risk factors for severe radiation retinopathy. Median visual acuity decreased by one Snellen chart line. When tumour distance to optic nerve or foveola is greater than 3 mm, there was minimal change to visual acuity. Conclusion: The findings demonstrate that high‐quality plaque brachytherapy can be delivered effectively at a statewide level.
- 7 October 2026
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
Choroidal Melanoma Treated With Ruthenium‐106 Eye Plaque Brachytherapy: Results of an Australian Statewide Service From November 2020 to January 2025
Introduction: Uveal melanoma is a rare but aggressive malignancy, predominantly affecting the choroid. This study is the first retrospective review performed on adult choroidal melanoma patients treated with Ruthenium‐106 plaque brachytherapy in Queensland. Method: The study period was November 2020 to January 2025, where patient, tumour, and treatment factors, as well as local control, salvage treatments, radiation retinopathy, and visual acuity were assessed at 6, 12, 24, and 36 months post‐treatment. Results: A total of 151 patients with a mean tumour thickness of 3.85 mm and mean largest basal diameter of 10.2 mm received treatment. A dose of 100 Gy to the tumour apex was prescribed to 88.7% of patients. The short‐term risk factor for disease progression was tumour thickness (odds ratio [OR] 2.01, 95% confidence interval [CI], 1.11–3.87; p = 0.025), whereas tumour to optic nerve distance was a protective factor in both the short‐ (OR 0.55, 95% CI 0.31–0.82; p = 0.013) and long‐term (OR 0.75, 95% CI 0.60–0.90; p = 0.005). At 36 months post‐treatment, local control was 89.5%, the enucleation rate was 3.3%, tumour thickness (OR 1.77, 95% CI 1.1–2.98; p = 0.022) and sclera dose (OR 1.01, 95% CI 1–1.01; p = 0.045) were risk factors for severe radiation retinopathy. Median visual acuity decreased by one Snellen chart line. When tumour distance to optic nerve or foveola is greater than 3 mm, there was minimal change to visual acuity. Conclusion: The findings demonstrate that high‐quality plaque brachytherapy can be delivered effectively at a statewide level.
- 23 September 2026
- Published by Springer Nature in Eye
- p. 1-4
Uveal melanoma in renal transplant recipients – a novel case series
- 23 September 2026
- Published by Springer Nature in Eye
- p. 1-4
Uveal melanoma in renal transplant recipients – a novel case series